Patents for A61P 35 - Antineoplastic agents (221,099)
04/2002
04/18/2002WO2001075038A3 A novel polypeptide - human atp- dependent serine protease 9 and the polynucleotide encoding said polypeptide
04/18/2002WO2001072955A3 Regulation of human nedd1-related protein
04/18/2002WO2001072777A3 Human transcription factors
04/18/2002WO2001072289A3 Medicament for the stimulation of leucopoiesis and treatment of tumour and protozoan diseases acarinosis and arthropod-borne diseases and a method for production thereof
04/18/2002WO2001070985A3 Bi-functional cancer treatment agents
04/18/2002WO2001068912A3 Diagnosis of diseases associated with tumor suppressor genes and oncogenes
04/18/2002WO2001068570A3 Il-8 receptor antagonists
04/18/2002WO2001068569A3 Il-8 receptor antagonists
04/18/2002WO2001068075A3 Method for increasing intestinal absorption of fat soluble vitamins in post-menopausal women and lower animals
04/18/2002WO2001068070A3 Use of spirolaxin for the treatment of diseases associated with abnormal angiogenesis
04/18/2002WO2001066595A3 Human fgf-23 gene and gene expression products
04/18/2002WO2001064681A3 3-(pyrolyllactone)-2-indolinone compounds as kinase inhibitors
04/18/2002WO2001058916A3 Antibodies to ccr5
04/18/2002WO2001058893A3 Indol-3-yl derivatives and their use as integrin inhibitors
04/18/2002WO2001058483A3 METHODS FOR THE PREVENTION AND TREATMENT OF INFECTIONS USING ANTI-C3b(i) ANTIBODIES
04/18/2002WO2001056601A3 Low dose haptenized tumor cell and tumor cell extract immunotherapy
04/18/2002WO2001052828A3 Glutamine prevention of delayed-onset irinotecan-induced diarrhea
04/18/2002WO2001049743A3 Methods of modulation of the immune system
04/18/2002WO2001046162A3 Novel 3-substituted 1,2,4-benzotriazines, a method for their production and the use thereof for the treatment and prophylaxis of tumours
04/18/2002WO2001040271A3 Cancer associated antigens and uses therefor
04/18/2002WO2001034202A3 Depletion of cellular coenzyme-a levels as a means to selectively kill cancer cells
04/18/2002WO2001026644A3 Mediators of hedgehog signaling pathways, compositions and uses related thereto
04/18/2002WO2001025437A3 Growth factor polypeptides and nucleic acids encoding same
04/18/2002WO2000071752A9 Assay for the detection of paclitaxel resistant cells in human tumors
04/18/2002WO2000070341A9 Methods, pharmaceutical formulations and kits for identification of subjects at risk for cancer
04/18/2002WO2000068387A9 Nucleic acids and proteins with interferon-beta activity
04/18/2002WO2000068385A9 Novel nucleic acids and proteins with growth hormone activity
04/18/2002WO2000067793A9 Death domain containing receptor 4
04/18/2002WO2000066106A9 Use of benzodiazepines for treating autoimmune diseases induced by apoptosis
04/18/2002US20020045777 Used to treat hypercholesterolemia, hyperlipemia, arteriosclerosis, vascular diseases, mycoses, gallstones, hyperproliferative disorders, and treatment and/or prophylaxis of impaired glucose tolerance and diabetes.
04/18/2002US20020045750 Asymetric hemisynthesis of harringtonines and their analogs, that are alkaloids used in chemotherapy.
04/18/2002US20020045663 Treating cancer in a patient comprising administering an effective amount of substantially purified D enantiomer of difluoromethylornithine
04/18/2002US20020045650 Substituted indole proteolytic enzyme inhibitors as cancer treating agents
04/18/2002US20020045645 Lactone integrin antagonists
04/18/2002US20020045644 2-phenylpyran-4-one derivatives
04/18/2002US20020045638 Method of treating estrogen receptor positive carcinoma
04/18/2002US20020045630 Antiproliferative, -carcinogenic, -tumor and -diabetic agents; binding to or modulating the human kinase insert-domain-containing receptor (KDR) or the murine fetal liver kinase 1 (FLK-1) receptor; vasculogenesis; angiogenesis
04/18/2002US20020045623 Stable; potent; penetrates cell membranes; effectively hinders cellular apoptosis; Antiinflammatory agents, Ischemic agents, cancer, autoimmune diseases and nervous system disorders.
04/18/2002US20020045613 1-aroyl-piperidinyl benzamidines
04/18/2002US20020045603 Method of inhibiting membrane-type matrix metalloproteinase
04/18/2002US20020045593 Use of the interferon receptor 2c polypeptide chain to enhance the anti-growth effects of type I interferons
04/18/2002US20020045570 Methods and compositions for degradation and/or inhibition of her-family tyrosine kinases
04/18/2002US20020045568 Use of mp52 0r mp121 for treating and preventing diseases of the nervous system
04/18/2002US20020045264 Expression vectors for use in gene therapy
04/18/2002US20020045257 Forming embryonic germ cells useful as model for studying imprinting; mate mammals, obtain embryo, dissociate embryonic cells, culturing the dissociated cells
04/18/2002US20020045241 T cells specific for kidney carcinoma
04/18/2002US20020045213 IL-17 receptor like molecules and uses thereof
04/18/2002US20020045203 Method for detecting active ingredients of medical value
04/18/2002US20020045162 Identification of viral agents in breast ducts and antiviral therapy therefore
04/18/2002US20020044973 Microparticles and their use in cancer treatment
04/18/2002US20020044972 Nucleic acid or oligonucleotide and a positively charged, aminated ethylene oxide-propylene oxide block copolymer
04/18/2002US20020044946 12-25 kDa bacterial proteins and their 116-58 kDa polymers useful in anti-tumor vaccines
04/18/2002US20020044937 Where the protein binds to T-cell cell surface protein, and that complex with nucleic acids, for transporting nucleic acids into human or animal cells which express the T-cell surface protein; antisense therapy, HIV therapy
04/18/2002US20020044936 Administering a monoclonal antibody or fragment thereof which acts as an antagonist of the integrins GPIIb/IIIa ( alpha IIb beta 3) and alpha v beta 3; also treating inflammatory diseases such as rheumatoid arthritis, psoriasis
04/18/2002US20020044919 Combinations and methods for treating neoplasms
04/18/2002US20020044909 Cyanine dye bioconjugates with bioactive molecules for diagnosis and therapy, particularly for visualization and detection of tumors
04/18/2002US20020044899 Controlled, super-fine grinding so particles react completely during leaching; extraction of copper from copper sulfide ores and concentrates
04/18/2002DE10049736A1 17alpha-Fluoralkylsteroide, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen 17alpha-Fluoroalkyl steroids, processes for their preparation and pharmaceutical compositions containing them
04/18/2002CA2765409A1 Hydroxamic acid compounds comprising a sulfonamide linkage as hdac inhibitors
04/18/2002CA2427499A1 Substituted indoles, pharmaceutical compositions containing such indoles and their use as ppar-.gamma. binding agents
04/18/2002CA2425835A1 Methods and compositions for nucleic acid delivery
04/18/2002CA2425828A1 Synthesis of epothilones and related analogs
04/18/2002CA2425809A1 Humanized anti-lt-.beta.-r antibodies
04/18/2002CA2425779A1 Compositions that inhibit proliferation of cancer cells
04/18/2002CA2425767A1 Lipocalins
04/18/2002CA2425678A1 Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
04/18/2002CA2425674A1 Sulfide and disulfide compounds and compositions for cholesterol management and related uses
04/18/2002CA2425649A1 Nitroderivatives as drugs for diseases having an inflammatory basis
04/18/2002CA2425643A1 Cancer-linked genes as targets for chemotherapy
04/18/2002CA2425632A1 Agents for the treatment of viral infections
04/18/2002CA2425610A1 Intracellular delivery of biological effectors by novel transporter peptide sequences
04/18/2002CA2425581A1 Modulation of ligand binding/enzymatic activity of alpha beta proteins
04/18/2002CA2425569A1 Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
04/18/2002CA2425508A1 Targeted therapeutic agents
04/18/2002CA2425416A1 Novel aminophenyl piperazine or aminophenyl piperidine derivatives inhibiting prenyl transferase proteins and methods for preparing same
04/18/2002CA2425407A1 Protecting therapeutic compositions from host-mediated inactivation
04/18/2002CA2425359A1 Dioxolane analogs for improved inter-cellular delivery
04/18/2002CA2425356A1 Hedgehog antagonists, methods and uses related thereto
04/18/2002CA2425121A1 Ether compounds and compositions for cholesterol management and related uses
04/18/2002CA2425001A1 Novel serine protease genes related to dppiv
04/18/2002CA2424983A1 Nucleic acid molecules and polypeptides for immune modulation
04/18/2002CA2424971A1 Topoisomerase inhibitors
04/18/2002CA2424823A1 Treatment of cancers by aplidine in conjunction with a myoprotector
04/18/2002CA2424785A1 Mediators of hedgehog signaling pathways, compositions and uses related thereto
04/18/2002CA2424438A1 Anhydro sugar derivatives of indolocarbazoles
04/18/2002CA2424317A1 Mammalian two-hybrid system for screening for modulators of the accumulation of metabolic products
04/18/2002CA2424299A1 Combination therapy for the treatment of estrogen-sensitive disease
04/18/2002CA2424292A1 Tricyclic compounds and uses thereof
04/18/2002CA2423515A1 Pyrazole derivatives for the treatment of viral diseases
04/18/2002CA2422718A1 Compositions and methods for prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with compositions comprising unfractionated cellular proteins
04/18/2002CA2394084A1 Inhibitors of protein kinases
04/17/2002EP1197556A1 Useful polypeptide
04/17/2002EP1197553A1 Antisense nucleic acid against alphaV integrin
04/17/2002EP1197550A2 Methods and compositions for diagnosing and treating disorders involving angiogenesis
04/17/2002EP1197491A1 Thioxanthenone antitumor agents
04/17/2002EP1197488A1 (2S)-2-(Adamantan-1-ylmethoxycarbonylamino)-3-(4-(2-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)ethyl)benzoylamino)propionic acid isopropyl ester, its preparation and its use
04/17/2002EP1197220A2 Therapeutic methods and compositions based on delta proteins and nucleic acids
04/17/2002EP1197218A1 Algae protein polysaccharide extraction and use thereof
04/17/2002EP1197211A1 Preventive and therapeutic agents for cancer
04/17/2002EP1197208A1 Sustained release compositions, process for producing the same and use thereof